Literature DB >> 25520773

How can we manage resistance to antiangiogenic drugs?

Dai Chu Luu1, Joseph Chao1.   

Abstract

Entities:  

Keywords:  CRLX101; HIF-1α; IL-17; angiogenesis; bevacizumab; drug resistance; neuropilin-1; preclinical models; predictive biomarkers; ramucirumab; β1-integrin

Year:  2014        PMID： 25520773      PMCID： PMC4266529          DOI： 10.4155/cli.14.46

Source DB:  PubMed          Journal:  Clin Investig (Lond)        ISSN： 2041-6792


× No keyword cloud information.
  15 in total

Review 1.  Neuropilin signalling in angiogenesis.

Authors:  Sina Koch
Journal:  Biochem Soc Trans       Date:  2012-02       Impact factor: 5.407

2.  Anti-IL-17 mAbs herald new options in psoriasis.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2012-06-07       Impact factor: 54.908

Review 3.  Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.

Authors:  Gabriel Limaverde-Sousa; Cinthya Sternberg; Carlos Gil Ferreira
Journal:  Cancer Treat Rev       Date:  2013-12-06       Impact factor: 12.111

4.  A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

Authors:  Amita Patnaik; Patricia M LoRusso; Wells A Messersmith; Kyriakos P Papadopoulos; Lia Gore; Muralidhar Beeram; Vanitha Ramakrishnan; Amy H Kim; Joseph C Beyer; L Mason Shih; Walter C Darbonne; Yan Xin; Ron Yu; Hong Xiang; Rainer K Brachmann; Colin D Weekes
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-17       Impact factor: 3.333

5.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Authors:  Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

Review 6.  β1 integrin: Critical path to antiangiogenic therapy resistance and beyond.

Authors:  Arman Jahangiri; Manish K Aghi; W Shawn Carbonell
Journal:  Cancer Res       Date:  2013-12-10       Impact factor: 12.701

7.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

8.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).

Authors:  Axel Grothey; Mary M Sugrue; David M Purdie; Wei Dong; Daniel Sargent; Eric Hedrick; Mark Kozloff
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

9.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Authors:  Eric Van Cutsem; Josep Tabernero; Radek Lakomy; Hans Prenen; Jana Prausová; Teresa Macarulla; Paul Ruff; Guy A van Hazel; Vladimir Moiseyenko; David Ferry; Joe McKendrick; Jonathan Polikoff; Alexia Tellier; Rémi Castan; Carmen Allegra
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

10.  Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.

Authors:  Shikha Gaur; Linling Chen; Terence Yen; Yafan Wang; Bingsen Zhou; Mark Davis; Yun Yen
Journal:  Nanomedicine       Date:  2011-10-25       Impact factor: 5.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.